Brought to you by 
FoldRx Pharmaceuticals gets $29mm through its Series C round
24 Jun 2010
Executive Summary
FoldRx Pharmaceuticals Inc. (developing cardiovascular, neurology, and respiratory therapeutics) has brought in $29mm through its Series C venture round. New backers Novo Ventures and Morgenthaler Ventures, which will each contribute one board member, were joined by current shareholders HealthCare Ventures, Fidelity Biosciences, TPG Biotechnology, Alta Partners, and Novartis Venture Funds.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
FoldRx Pharmaceuticals gets $29mm through its Series C round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice